What is Barinthus Biotherapeutics plc's earnings per share (EPS)?

Barinthus Biotherapeutics plc (BRNS) reported diluted earnings per share of $-1.64 for fiscal year 2025. This represents a -5.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Barinthus Biotherapeutics plc Financials

BRNS

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Barinthus Biotherapeutics plc (BRNS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 49/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth

Barinthus Biotherapeutics plc's revenue declined 100% year-over-year, from $15.0M to $0. This contraction results in a growth score of 0/100.

Leverage

Barinthus Biotherapeutics plc carries a low D/E ratio of 0.32, meaning only $0.32 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 7.76, Barinthus Biotherapeutics plc holds $7.76 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Barinthus Biotherapeutics plc generates a -89.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -47.0% the prior year.

Piotroski F-Score Weak

1/9

Barinthus Biotherapeutics plc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.72x

For every $1 of reported earnings, Barinthus Biotherapeutics plc generates $0.72 in operating cash flow (-$48.0M OCF vs -$66.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1383.4x

Barinthus Biotherapeutics plc earns $-1383.4 in operating income for every $1 of interest expense (-$70.6M vs $51K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

Barinthus Biotherapeutics plc generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

EBITDA

-$64.7M

YoY-4.1%

Barinthus Biotherapeutics plc's EBITDA was -$64.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.1% from the prior year.

Net Income

-$66.4M

YoY-8.8%

Barinthus Biotherapeutics plc reported -$66.4M in net income in fiscal year 2025. This represents a decrease of 8.8% from the prior year.

EPS (Diluted)

$-1.64

YoY-5.8%

Barinthus Biotherapeutics plc earned $-1.64 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 5.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$48.0M

YoY-61.0%

Barinthus Biotherapeutics plc generated -$48.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 61.0% from the prior year.

Cash & Debt

$70.5M

YoY-36.3%

5Y CAGR+10.2%

Barinthus Biotherapeutics plc held $70.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

41M

YoY+1.5%

5Y CAGR+38.7%

Barinthus Biotherapeutics plc had 41M shares outstanding in fiscal year 2025. This represents an increase of 1.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-89.5%

YoY-42.5pp

Barinthus Biotherapeutics plc's ROE was -89.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 42.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$25.6M

YoY-39.5%

5Y CAGR+12.2%

Barinthus Biotherapeutics plc invested $25.6M in research and development in fiscal year 2025. This represents a decrease of 39.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$37K

YoY-95.9%

5Y CAGR-33.9%

Barinthus Biotherapeutics plc invested $37K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 95.9% from the prior year.

BRNS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0-100.0%	$15.0M+1766.5%	$802K-98.2%	$44.7M+16580.2%	$268K-94.4%	$4.8M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$25.6M-39.5%	$42.2M-5.9%	$44.9M+6.0%	$42.4M+107.9%	$20.4M+41.6%	$14.4M
SG&A Expenses	$40.8M+37.6%	$29.7M-25.5%	$39.8M+523.1%	$6.4M-74.5%	$25.1M+139.7%	$10.5M
Operating Income	-$70.6M-3.8%	-$68.0M+19.0%	-$83.9M-1976.6%	-$4.0M+91.1%	-$45.2M-125.6%	-$20.0M
Interest Expense	$51K-3.8%	$53K+89.3%	$28K+47.4%	$19K-99.3%	$2.7M-25.9%	$3.6M
Income Tax	-$175K-297.7%	-$44K+98.6%	-$3.1M+31.2%	-$4.5M-15867.9%	-$28K-129.5%	$95K
Net Income	-$66.4M-8.8%	-$61.1M+16.7%	-$73.3M-1473.0%	$5.3M+110.5%	-$50.9M-187.3%	-$17.7M
EPS (Diluted)	$-1.64-5.8%	$-1.55+18.8%	$-1.91-1464.3%	$0.14+107.1%	$-1.96+12.5%	$-2.24

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	$0	N/A	N/A	N/A	$15.0M	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$5.4M-32.2%	$8.0M-4.1%	$8.3M	N/A	$11.1M-4.5%	$11.7M+4.8%	$11.1M
SG&A Expenses	N/A	$5.2M-66.4%	$15.4M+21.7%	$12.6M	N/A	$13.4M+86.4%	$7.2M+20.1%	$6.0M
Operating Income	N/A	-$15.1M+35.4%	-$23.3M-13.2%	-$20.6M	N/A	-$9.4M+48.7%	-$18.3M-8.1%	-$16.9M
Interest Expense	N/A	$13K+8.3%	$12K-7.7%	$13K	N/A	$17K+41.7%	$12K0.0%	$12K
Income Tax	N/A	-$71K-184.0%	-$25K-13.6%	-$22K	N/A	-$3K+57.1%	-$7K+81.1%	-$37K
Net Income	N/A	-$14.6M+31.0%	-$21.1M-7.5%	-$19.6M	N/A	-$8.1M+52.1%	-$16.9M-9.3%	-$15.5M
EPS (Diluted)	N/A	$-0.36+30.8%	$-0.52-6.1%	$-0.49	N/A	$-0.21+51.2%	$-0.43-7.5%	$-0.40

BRNS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$98.2M-38.8%	$160.3M-25.3%	$214.5M-20.6%	$270.2M-3.7%	$280.7M+454.1%	$50.7M
Current Assets	$77.8M-38.1%	$125.7M-19.9%	$156.9M-26.3%	$213.0M-6.1%	$226.8M+373.4%	$47.9M
Cash & Equivalents	$70.5M-36.3%	$110.7M-22.1%	$142.1M-26.9%	$194.4M-9.2%	$214.1M+394.7%	$43.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$323K+1515.0%	$20K-96.1%	$518K
Goodwill	N/A	$0-100.0%	$12.2M0.0%	$12.2M-3.3%	$12.6M	N/A
Total Liabilities	$23.9M-20.9%	$30.2M+9.7%	$27.5M+1.9%	$27.0M-4.1%	$28.2M-67.9%	$87.6M
Current Liabilities	$10.0M-36.0%	$15.7M+24.3%	$12.6M+2.9%	$12.2M+9.7%	$11.2M+46.0%	$7.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$74.2M-42.9%	$130.0M-30.4%	$186.8M-23.1%	$242.9M-3.7%	$252.1M+783.0%	-$36.9M
Retained Earnings	-$304.1M-28.0%	-$237.7M-34.6%	-$176.6M-71.0%	-$103.2M+4.9%	-$108.6M-88.1%	-$57.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$98.2M-10.1%	$109.2M-15.7%	$129.6M-8.8%	$142.0M-11.4%	$160.3M-15.0%	$188.7M+1.0%	$186.7M-6.4%	$199.5M
Current Assets	$77.8M-10.4%	$86.8M-13.6%	$100.4M-8.6%	$109.9M-12.6%	$125.7M-6.6%	$134.7M+2.1%	$131.9M-7.9%	$143.1M
Cash & Equivalents	$70.5M-5.1%	$74.3M-13.9%	$86.3M-13.0%	$99.1M-10.4%	$110.7M+4.3%	$106.1M-9.9%	$117.8M-9.4%	$130.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	$0-100.0%	$12.2M0.0%	$12.2M0.0%	$12.2M
Total Liabilities	$23.9M-3.1%	$24.6M-9.0%	$27.1M+2.6%	$26.4M-12.5%	$30.2M+3.3%	$29.2M-2.4%	$30.0M+9.1%	$27.5M
Current Liabilities	$10.0M-7.2%	$10.8M-15.1%	$12.7M+6.3%	$12.0M-23.5%	$15.7M+3.9%	$15.1M-3.3%	$15.6M+21.5%	$12.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$74.2M-12.1%	$84.5M-17.5%	$102.4M-11.4%	$115.5M-11.2%	$130.0M-18.4%	$159.3M+1.7%	$156.6M-8.9%	$171.8M
Retained Earnings	-$304.1M-3.8%	-$293.0M-5.2%	-$278.4M-8.2%	-$257.3M-8.3%	-$237.7M-9.5%	-$217.1M-3.9%	-$209.0M-8.8%	-$192.1M

BRNS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$48.0M-65.8%	-$28.9M+43.2%	-$50.9M-252.9%	-$14.4M+55.7%	-$32.6M-195.5%	-$11.0M
Capital Expenditures	$37K-95.9%	$892K-83.5%	$5.4M-11.8%	$6.1M+435.6%	$1.1M+291.1%	$293K
Free Cash Flow	-$48.0M-61.0%	-$29.8M+47.0%	-$56.3M-173.9%	-$20.6M+39.0%	-$33.7M-197.9%	-$11.3M
Investing Cash Flow	$416K+146.6%	-$892K+83.5%	-$5.4M+5.9%	-$5.8M+55.5%	-$12.9M-4306.8%	-$293K
Financing Cash Flow	$2K-99.9%	$2.2M+15.5%	$1.9M+476.0%	$325K-99.9%	$222.7M+437.6%	$41.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$4.2M+60.5%	-$10.7M+40.8%	-$18.1M-21.5%	-$14.9M-213.9%	$13.1M+171.9%	-$18.2M-51.6%	-$12.0M-1.6%	-$11.8M
Capital Expenditures	$0	$0-100.0%	$32K+540.0%	$5K-98.2%	$278K+143.9%	$114K-40.6%	$192K-37.7%	$308K
Free Cash Flow	-$4.2M+60.5%	-$10.7M+40.9%	-$18.1M-21.7%	-$14.9M-216.4%	$12.8M+169.9%	-$18.3M-50.1%	-$12.2M-0.6%	-$12.1M
Investing Cash Flow	$2K-99.6%	$451K+1509.4%	-$32K-540.0%	-$5K+98.2%	-$278K-143.9%	-$114K+40.6%	-$192K+37.7%	-$308K
Financing Cash Flow	$0	$0	$0-100.0%	$2K-99.8%	$837K+80.0%	$465K+29.9%	$358K-28.8%	$503K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BRNS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-454.1%+10009.0pp	-10463.1%-10454.0pp	-9.0%+16864.5pp	-16873.5%-16457.7pp	-415.8%
Net Margin	N/A	-408.0%+8737.5pp	-9145.5%-9157.5pp	11.9%+18991.4pp	-18979.5%-18612.2pp	-367.3%
Return on Equity	-89.5%-42.5pp	-47.0%-7.7pp	-39.3%-41.5pp	2.2%+22.4pp	-20.2%	N/A
Return on Assets	-67.7%-29.6pp	-38.1%-3.9pp	-34.2%-36.2pp	2.0%+20.1pp	-18.1%+16.8pp	-34.9%
Current Ratio	7.76-0.3	8.03-4.4	12.45-4.9	17.40-2.9	20.32+14.1	6.27
Debt-to-Equity	0.32+0.1	0.23+0.1	0.15+0.0	0.110.0	0.11+2.5	-2.37
FCF Margin	N/A	-199.3%+6825.4pp	-7024.7%-6978.7pp	-46.0%+12539.4pp	-12585.5%-12350.6pp	-234.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	-62.7%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-54.2%	N/A	N/A
Return on Equity	N/A	-17.3%+3.4pp	-20.6%-3.6pp	-17.0%	N/A	-5.1%+5.7pp	-10.8%-1.8pp	-9.0%
Return on Assets	N/A	-13.3%+3.0pp	-16.3%-2.5pp	-13.8%	N/A	-4.3%+4.8pp	-9.1%-1.3pp	-7.8%
Current Ratio	7.76-0.3	8.04+0.1	7.89-1.3	9.18+1.1	8.03-0.9	8.93+0.5	8.46-2.7	11.15
Debt-to-Equity	0.32+0.0	0.29+0.0	0.26+0.0	0.230.0	0.23+0.0	0.180.0	0.19+0.0	0.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	-122.3%	N/A	N/A

Similar Companies

Tempest Therapeutics Inc TPST

$22.8M

Plus Therapeutics Inc PSTV

$22.9M

Radiopharm Theranostics Ltd RADX

$34.8M

Annovis Bio Inc ANVS

$66.6M

Century Therapeutics, Inc. IPSC

$393.6M

Frequently Asked Questions

What is Barinthus Biotherapeutics plc's annual revenue?

Barinthus Biotherapeutics plc (BRNS) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Barinthus Biotherapeutics plc's revenue growing?

Barinthus Biotherapeutics plc (BRNS) revenue declined by 100% year-over-year, from $15.0M to $0 in fiscal year 2025.

Is Barinthus Biotherapeutics plc profitable?

No, Barinthus Biotherapeutics plc (BRNS) reported a net income of -$66.4M in fiscal year 2025.

What is Barinthus Biotherapeutics plc's EBITDA?

Barinthus Biotherapeutics plc (BRNS) had EBITDA of -$64.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Barinthus Biotherapeutics plc's return on equity (ROE)?

Barinthus Biotherapeutics plc (BRNS) has a return on equity of -89.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Barinthus Biotherapeutics plc's free cash flow?

Barinthus Biotherapeutics plc (BRNS) generated -$48.0M in free cash flow during fiscal year 2025. This represents a -61.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Barinthus Biotherapeutics plc's operating cash flow?

Barinthus Biotherapeutics plc (BRNS) generated -$48.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Barinthus Biotherapeutics plc's total assets?

Barinthus Biotherapeutics plc (BRNS) had $98.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Barinthus Biotherapeutics plc's capital expenditures?

Barinthus Biotherapeutics plc (BRNS) invested $37K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Barinthus Biotherapeutics plc spend on research and development?

Barinthus Biotherapeutics plc (BRNS) invested $25.6M in research and development during fiscal year 2025.

How many shares does Barinthus Biotherapeutics plc have outstanding?

Barinthus Biotherapeutics plc (BRNS) had 41M shares outstanding as of fiscal year 2025.

What is Barinthus Biotherapeutics plc's current ratio?

Barinthus Biotherapeutics plc (BRNS) had a current ratio of 7.76 as of fiscal year 2025, which is generally considered healthy.

What is Barinthus Biotherapeutics plc's debt-to-equity ratio?

Barinthus Biotherapeutics plc (BRNS) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Barinthus Biotherapeutics plc's return on assets (ROA)?

Barinthus Biotherapeutics plc (BRNS) had a return on assets of -67.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Barinthus Biotherapeutics plc's cash runway?

Based on fiscal year 2025 data, Barinthus Biotherapeutics plc (BRNS) had $70.5M in cash against an annual operating cash burn of $48.0M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Barinthus Biotherapeutics plc's Piotroski F-Score?

Barinthus Biotherapeutics plc (BRNS) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Barinthus Biotherapeutics plc's earnings high quality?

Barinthus Biotherapeutics plc (BRNS) has an earnings quality ratio of 0.72x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Barinthus Biotherapeutics plc cover its interest payments?

Barinthus Biotherapeutics plc (BRNS) has an interest coverage ratio of -1383.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Barinthus Biotherapeutics plc?

Barinthus Biotherapeutics plc (BRNS) scores 49 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.